Exemestane

• CAT Number: A001005
• CAS Number: 107868-30-4
• Molecular Formula: C20H24O2
• Molecular Weight: 296.4
• Purity: ≥95%
• Synonyms: PNU155971; PNU-155971; PNU 155971; FCE24304; FCE-24304; FCE 24304; Exemestane; US brand name: Aromasin.
• Target: Cytochrome P450
• Solubility: DMSO: ≥ 54 mg/mL
• Storage: -20°C
• IUPAC Name: (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
• InChI: InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
• InChIKey: FYIZQONLCFLEV-DAELLWKTSA-N
• SMILES: CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C

Exemestane (CAT: A001005), commercially known as Aromasin, is a medication used for the treatment of breast cancer, particularly those classified as estrogen receptor-positive (ER-positive) or hormonally-responsive. Its mechanism of action centers on its role as an aromatase inhibitor, effectively blocking the synthesis of estrogen in the body.

Overview of Clinical Research

Exemestane is an aromatase inhibitor as well as an estrogen receptor antagonist. Pfizer completed the phase III trial in Breast cancer in 2018.

Reference

1: Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O/'Shaughnessy J, Parulekar WR, Liedke PER, Chen BE, Goss PE. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. Eur J Cancer. 2017 Dec 20;90:19-25. doi: 10.1016/j.ejca.2017.11.014. [Epub ahead of print] PubMed PMID: 29274617.
2: Nuvoli B, Camera E, Mastrofrancesco A, Briganti S, Galati R. Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane. Free Radic Biol Med. 2017 Dec 9;115:266-277. doi: 10.1016/j.freeradbiomed.2017.12.008. [Epub ahead of print] PubMed PMID: 29229551.
3: Mangas C, Espeli V, Blum R. A Case of Eruptive Disseminated Porokeratosis in a Cancer Patient after Trastuzumab and Exemestane Treatment: Cancer Related or Drug Induced Phenomenon? Actas Dermosifiliogr. 2017 Dec 5. pii: S0001-7310(17)30594-X. doi: 10.1016/j.ad.2017.07.021. [Epub ahead of print] English, Spanish. PubMed PMID: 29221608.
4: Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee. Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast Cancer Res Treat. 2017 Nov 24. doi: 10.1007/s10549-017-4543-7. [Epub ahead of print] PubMed PMID: 29177605.
5: Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, Raad R, Goldberg JD, Unutmaz D, Adams S. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4570-4. [Epub ahead of print] PubMed PMID: 29124456.
6: Ciruelos E, Vidal M, Martínez de Dueñas E, Martínez-Jáñez N, Fernández Y, García-Sáenz JA, Murillo L, Carabantes F, Beliera A, Fonseca R, Gavilá J. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain. Clin Transl Oncol. 2017 Nov 7. doi: 10.1007/s12094-017-1784-1. [Epub ahead of print] PubMed PMID: 29116433.
7: Elzoghby AO, El-Lakany SA, Helmy MW, Abu-Serie MM, Elgindy NA. Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy. Nanomedicine (Lond). 2017 Dec;12(24):2785-2805. doi: 10.2217/nnm-2017-0247. Epub 2017 Nov 2. PubMed PMID: 29094642.
8: Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D/'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. Sci Rep. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2. PubMed PMID: 28878375; PubMed Central PMCID: PMC5587713.
9: Gregory BJ, Chen SM, Murphy MA, Atchley DH, Kamdem LK. Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers. J Clin Pharm Ther. 2017 Oct;42(5):547-553. doi: 10.1111/jcpt.12569. Epub 2017 Jul 29. PubMed PMID: 28868654; PubMed Central PMCID: PMC5646416.
10: Stolarczyk EU, Rosa A, Kubiszewski M, Zagrodzka J, Cybulski M, Kaczmarek Ł. Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development. Eur J Pharm Sci. 2017 Nov 15;109:389-401. doi: 10.1016/j.ejps.2017.08.033. Epub 2017 Sep 1. PubMed PMID: 28865686.